Enzalutamide in metastatic prostate cancer before chemotherapy

Tomasz M Beer; Andrew J Armstrong; Dana E Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Suman Bhattacharya; Joan Carles; Simon Chowdhury; Ian Davis; Johann S De Bono; Christopher P Evans; Karim Fizazi; Anthony Michael Joshua; Choung-Soo Kim; Go Kimura; Paul N Mainwaring; Harry Mansbach; Kurt Miller; Sarah B Noonberg; Frank Perabo; De Phung; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Peter M Venner; Bertrand Tombal

doi:10.1056/NEJMoa1405095

Enzalutamide in metastatic prostate cancer before chemotherapy

Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, Yohann Loriot, Cora N Sternberg, Celestia S Higano, Peter Iversen, Suman Bhattacharya, Joan Carles, Simon Chowdhury, Ian Davis, Johann S De Bono, Christopher P Evans, Karim Fizazi, Anthony Michael Joshua, Choung-Soo Kim, Go Kimura, Paul N Mainwaring, Harry Mansbach, Kurt MillerSarah B Noonberg, Frank Perabo, De Phung, Fred Saad, Howard I Scher, Mary-Ellen Taplin, Peter M Venner, Bertrand Tombal

Eastern Health Clinical School

Research output: Contribution to journal › Article › Research › peer-review

2075 Citations (Scopus)

Abstract

Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy.

Original language	English
Pages (from-to)	424 - 433
Number of pages	10
Journal	The New England Journal of Medicine
Volume	371
Issue number	5
DOIs	https://doi.org/10.1056/NEJMoa1405095
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/NEJMoa1405095

Cite this

Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., Davis, I., De Bono, J. S., Evans, C. P., Fizazi, K., Joshua, A. M., Kim, C.-S., Kimura, G., Mainwaring, P. N., Mansbach, H., ... Tombal, B. (2014). Enzalutamide in metastatic prostate cancer before chemotherapy. The New England Journal of Medicine, 371(5), 424 - 433. https://doi.org/10.1056/NEJMoa1405095

@article{c5b63afb161d40a99645fc9f954621d2,

title = "Enzalutamide in metastatic prostate cancer before chemotherapy",

abstract = "Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy.",

author = "Beer, {Tomasz M} and Armstrong, {Andrew J} and Rathkopf, {Dana E} and Yohann Loriot and Sternberg, {Cora N} and Higano, {Celestia S} and Peter Iversen and Suman Bhattacharya and Joan Carles and Simon Chowdhury and Ian Davis and {De Bono}, {Johann S} and Evans, {Christopher P} and Karim Fizazi and Joshua, {Anthony Michael} and Choung-Soo Kim and Go Kimura and Mainwaring, {Paul N} and Harry Mansbach and Kurt Miller and Noonberg, {Sarah B} and Frank Perabo and De Phung and Fred Saad and Scher, {Howard I} and Mary-Ellen Taplin and Venner, {Peter M} and Bertrand Tombal",

year = "2014",

doi = "10.1056/NEJMoa1405095",

language = "English",

volume = "371",

pages = "424 -- 433",

journal = "The New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "5",

}

Beer, TM, Armstrong, AJ, Rathkopf, DE, Loriot, Y, Sternberg, CN, Higano, CS, Iversen, P, Bhattacharya, S, Carles, J, Chowdhury, S, Davis, I, De Bono, JS, Evans, CP, Fizazi, K, Joshua, AM, Kim, C-S, Kimura, G, Mainwaring, PN, Mansbach, H, Miller, K, Noonberg, SB, Perabo, F, Phung, D, Saad, F, Scher, HI, Taplin, M-E, Venner, PM & Tombal, B 2014, 'Enzalutamide in metastatic prostate cancer before chemotherapy', The New England Journal of Medicine, vol. 371, no. 5, pp. 424 - 433. https://doi.org/10.1056/NEJMoa1405095

TY - JOUR

T1 - Enzalutamide in metastatic prostate cancer before chemotherapy

AU - Beer, Tomasz M

AU - Armstrong, Andrew J

AU - Rathkopf, Dana E

AU - Loriot, Yohann

AU - Sternberg, Cora N

AU - Higano, Celestia S

AU - Iversen, Peter

AU - Bhattacharya, Suman

AU - Carles, Joan

AU - Chowdhury, Simon

AU - Davis, Ian

AU - De Bono, Johann S

AU - Evans, Christopher P

AU - Fizazi, Karim

AU - Joshua, Anthony Michael

AU - Kim, Choung-Soo

AU - Kimura, Go

AU - Mainwaring, Paul N

AU - Mansbach, Harry

AU - Miller, Kurt

AU - Noonberg, Sarah B

AU - Perabo, Frank

AU - Phung, De

AU - Saad, Fred

AU - Scher, Howard I

AU - Taplin, Mary-Ellen

AU - Venner, Peter M

AU - Tombal, Bertrand

PY - 2014

Y1 - 2014

N2 - Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy.

AB - Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy.

UR - http://www.nejm.org/doi/pdf/10.1056/NEJMoa1405095

U2 - 10.1056/NEJMoa1405095

DO - 10.1056/NEJMoa1405095

M3 - Article

SN - 0028-4793

VL - 371

SP - 424

EP - 433

JO - The New England Journal of Medicine

JF - The New England Journal of Medicine

IS - 5

ER -

Enzalutamide in metastatic prostate cancer before chemotherapy

Abstract

UN SDGs

Access to Document

Other files and links

Cite this